奈克塔制药

最新新闻

• 评级变动
  TD Cowen Initiates Nektar Therapeutics(NKTR.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/3/17
• 评级变动
  Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $192
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $123
  \u5e02\u573a\u8d44\u8baf · 2026/4/7
• 评级变动
  A Quick Look at Today's Ratings for Nektar Therapeutics(NKTR.US), With a Forecast Between $80 to $192
  \u5e02\u573a\u8d44\u8baf · 2026/8/15
• BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $178
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• William Blair Maintains Nektar Therapeutics(NKTR.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $192
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 评级变动
  TD Cowen Maintains Nektar Therapeutics(NKTR.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  CCORF Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $153
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $151
  \u5e02\u573a\u8d44\u8baf · 2026/4/21
• Jefferies Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $150
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $123
  \u5e02\u573a\u8d44\u8baf · 2026/3/16
• 评级变动
  H.C. Wainwright Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Cuts Target Price to $135
  \u5e02\u573a\u8d44\u8baf · 2026/4/6
• 评级变动
  CCORF Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $153
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  H.C. Wainwright Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $165
  \u5e02\u573a\u8d44\u8baf · 2026/3/17
• 评级变动
  A Quick Look at Today's Ratings for Nektar Therapeutics(NKTR.US), With a Forecast Between $134 to $185
  \u5e02\u573a\u8d44\u8baf · 2026/4/21
• 评级变动
  Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $105
  \u5e02\u573a\u8d44\u8baf · 2026/3/13
• 评级变动
  Oppenheimer Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $140
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• H.C. Wainwright Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $185
  \u5e02\u573a\u8d44\u8baf · 2026/10/3
• Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $151
  \u5e02\u573a\u8d44\u8baf · 2026/10/5

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。